Dissecting cellular responses to irradiation via targeted disruptions of the ATM-CHK1-PP2A circuit

Cell Cycle

Volumn 12, Issue 7, 2013, Pages 1105-1118

  Palii, Stela S ^a   Cui, Yuxia ^a   Innes, Cynthia L ^a   Paules, Richard S ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Ataxia telangiectasia mutated; Checkpoint kinase 1; DNA damage; Feedback regulation; Phosphatase

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 2;

ARTICLE; CELL CYCLE ARREST; CELL DISRUPTION; CELL LINE; CELL SELECTION; CONTROLLED STUDY; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; M PHASE CELL CYCLE CHECKPOINT; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION;

EID: 84875906237     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24127     Document Type: Article

References (50)

1. Martín M, Terradas M, Tusell L, Genescà A. ATM and DNA-PKcs make a complementary couple in DNA double-strand break repair. Mutat Res 2012; 751:29- 35; PMID:22230547; http://dx.doi.org/10.1016/j. mrrev.2011.12.006
2. Smith J, Tho LM, Xu N, Gillespie DA. The ATMChk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108:73-112; PMID:21034966; http://dx.doi.org/10.1016/B978-0- 12-380888-2.00003-0
3. Kass EM, Jasin M. Collaboration and competition between DNA double-strand break repair pathways. FEBS Lett 2010; 584:3703-8; PMID:20691183; http://dx.doi.org/10.1016/j.febslet.2010.07.057
4. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008; 18:134-47; PMID:18157161; http://dx.doi. org/10.1038/cr.2007.111
5. Sørensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7:195- 201; PMID:15665856; http://dx.doi.org/10.1038/ncb1212
6. Enders GH. Expanded roles for Chk1 in genome maintenance. J Biol Chem 2008; 283:17749-52; PMID:18424430; http://dx.doi.org/10.1074/jbc. R800021200
7. Ha K, Lee GE, Palii SS, Brown KD, Takeda Y, Liu K, et al. Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet 2011; 20:126- 40; PMID:20940144; http://dx.doi.org/10.1093/hmg/ddq451
8. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2'- deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 2008; 28:752- 71; PMID:17991895; http://dx.doi.org/10.1128/MCB.01799- 07
9. Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H, et al. Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell 2008; 132:221-32; PMID:18243098; http://dx.doi.org/10.1016/j. cell.2007.12.013
10. Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 2008; 98:523-8; PMID:18231106; http://dx.doi.org/10.1038/sj.bjc.6604208
11. Dai Y, Grant S. Targeting Chk1 in the replicative stress response. Cell Cycle 2010; 9:1025; PMID:20237419; http://dx.doi.org/10.4161/cc.9.6.11155
12. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17:88-96; PMID:21087899; http://dx.doi.org/10.1016/j.molmed. 2010.10.009
13. Arlander SJ, Greene BT, Innes CL, Paules RS. DNA protein kinase-dependent G2 checkpoint revealed following knockdown of ataxia-telangiectasia mutated in human mammary epithelial cells. Cancer Res 2008; 68:89-97; PMID:18172300; http://dx.doi. org/10.1158/0008-5472.CAN-07-0675
14. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006; 26:7529-38; PMID:17015476; http://dx.doi.org/10.1128/MCB.00447-06
15. Freeman AK, Monteiro AN. Phosphatases in the cellular response to DNA damage. Cell Commun Signal 2010; 8:27; PMID:20860841; http://dx.doi. org/10.1186/1478-811X-8-27
16. Shouse GP, Cai X, Liu X. Serine 15 phosphorylation of p53 directs its interaction with B56g and the tumor suppressor activity of B56g-specific protein phosphatase 2A. Mol Cell Biol 2008; 28:448- 56; PMID:17967874; http://dx.doi.org/10.1128/MCB.00983-07
17. Yan Y, Cao PT, Greer PM, Nagengast ES, Kolb RH, Mumby MC, et al. Protein phosphatase 2A has an essential role in the activation of g-irradiation-induced G2/M checkpoint response. Oncogene 2010; 29:4317- 29; PMID:20498628; http://dx.doi.org/10.1038/onc.2010.187
18. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992; 257:1261- 4; PMID:1325671; http://dx.doi.org/10.1126/science. 1325671
19. Chen J, Parsons S, Brautigan DL. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts. J Biol Chem 1994; 269:7957-62; PMID:7510677
20. Ray S, Anderson ME, Tegtmeyer P. Differential interaction of temperature-sensitive simian virus 40 T antigens with tumor suppressors pRb and p53. J Virol 1996; 70:7224-7; PMID:8794371
21. Meyer KM, Hess SM, Tlsty TD, Leadon SA. Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene 1999; 18:5795- 805; PMID:10523860; http://dx.doi.org/10.1038/sj.onc.1202977
22. Troester MA, Hoadley KA, Sørlie T, Herbert BS, Børresen-Dale AL, Lønning PE, et al. Cell-typespecific responses to chemotherapeutics in breast cancer. Cancer Res 2004; 64:4218-26; PMID:15205334; http://dx.doi.org/10.1158/0008-5472.CAN-04-0107
23. Zhang J, Pickering CR, Holst CR, Gauthier ML, Tlsty TD. p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res 2006; 66:10325-31; PMID:17079452; http://dx.doi. org/10.1158/0008-5472.CAN-06-1594
24. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009; 23:1895- 909; PMID:19608766; http://dx.doi.org/10.1101/gad.1815309
25. Gagou ME, Zuazua-Villar P, Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell 2010; 21:739-52; PMID:20053681; http://dx.doi. org/10.1091/mbc.E09-07-0618
26. Kim MA, Kim HJ, Brown AL, Lee MY, Bae YS, Park JI, et al. Identification of novel substrates for human checkpoint kinase Chk1 and Chk2 through genome-wide screening using a consensus Chk phosphorylation motif. Exp Mol Med 2007; 39:205- 12; PMID:17464182; http://dx.doi.org/10.1038/emm.2007.23
27. Lee HJ, Hwang HI, Jang YJ. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway. Cell Cycle 2010; 9:2389-98; PMID:20581453; http://dx.doi. org/10.4161/cc.9.12.11904
28. Bertoni F, Codegoni AM, Furlan D, Tibiletti MG, Capella C, Broggini M. CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer 1999; 26:176-80; PMID:10469457
29. Menoyo A, Alazzouzi H, Espín E, Armengol M, Yamamoto H, Schwartz S Jr. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res 2001; 61:7727-30; PMID:11691784
30. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev 2000; 14:1448-59; PMID:10859164
31. Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004; 6:45- 59; PMID:15261141; http://dx.doi.org/10.1016/j. ccr.2004.06.015
32. Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A, et al. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 2010; 29:4007-17; PMID:20473325; http://dx.doi. org/10.1038/onc.2010.163
33. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER-2- breast carcinomas. Cancer Res 2007; 67:6574-81; PMID:17638866; http://dx.doi.org/10. 1158/0008- 5472.CAN-06-3545
34. Tort F, Hernández S, Beà S, Camacho E, Fernández V, Esteller M, et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia 2005; 19:112-7; PMID:15526025
35. Chen P, Gatei M, O'Connell MJ, Khanna KK, Bugg SJ, Hogg A, et al. Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells. Oncogene 1999; 18:249-56; PMID:9926940; http://dx.doi.org/10.1038/sj.onc.1202257
36. Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011; 10:2121-8; PMID:21610326; http://dx.doi.org/10.4161/cc.10.13.16398
37. Ashwell S. Checkpoint kinase and Wee1 inhibitors as anticancer therapeutics. Elsevier Ltd., 2012:211-34
38. Davies KD, Humphries MJ, Sullivan FX, von Carlowitz I, Le Huerou Y, Mohr PJ, et al. Single-agent inhibition of Chk1 is antiproliferative in human cancer cell lines in vitro and inhibits tumor xenograft growth in vivo. Oncol Res 2011; 19:349-63; PMID:21936404; http://dx.doi.org/10.3727/096504011X13079697132961
39. Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv 2011; 11:133- 40; PMID:21540473; http://dx.doi.org/10.1124/mi.11.2.11
40. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci 2011; 32:308-16; PMID:21458083; http://dx.doi.org/10.1016/j.tips.2011.02.014
41. Ren Q, Liu R, Dicker A, Wang Y. CHK1 affects cell sensitivity to microtubule-targeted drugs. J Cell Physiol 2005; 203:273-6; PMID:15389625; http://dx.doi.org/10.1002/jcp.20222
42. Greenow KR, Clarke AR, Jones RH. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 2009; 28:1443-53; PMID:19169280; http://dx.doi.org/10. 1038/onc.2008.482
43. Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, et al. Disruption of Src function potentiates Chk1- inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2011; 117:1947-57; PMID:21148814; http://dx.doi.org/10.1182/blood- 2010-06-291146
44. Tao Y, Leteur C, Yang C, Zhang P, Castedo M, Pierré A, et al. Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 2009; 8:1196-205; PMID:19305158; http://dx.doi.org/10.4161/cc.8.8.8203
45. Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, et al. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011; 12:788- 96; PMID:21892012; http://dx.doi.org/10.4161/cbt.12.9.17673
46. Lu HR, Wang X, Wang Y. A stronger DNA damageinduced G2 checkpoint due to over-activated CHK1 in the absence of PARP-1. Cell Cycle 2006; 5:2364- 70; PMID:17102615; http://dx.doi.org/10.4161/cc.5.20.3355
47. Jurvansuu J, Fragkos M, Ingemarsdotter C, Beard P. Chk1 instability is coupled to mitotic cell death of p53-deficient cells in response to virus-induced DNA damage signaling. J Mol Biol 2007; 372:397- 406; PMID:17663993; http://dx.doi.org/10.1016/j. jmb.2007.06.077
48. Limbo O, Porter-Goff ME, Rhind N, Russell P. Mre11 nuclease activity and Ctp1 regulate Chk1 activation by Rad3ATR and Tel1ATM checkpoint kinases at double-strand breaks. Mol Cell Biol 2011; 31:573- 83; PMID:21098122; http://dx.doi.org/10.1128/MCB.00994-10
49. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010; 70:4972-81; PMID:20501833; http://dx.doi. org/10.1158/0008-5472.CAN-09-3573
50. Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, et al. Assessment of Chk1 phosphorylation as a pharmacodynamic biomarker of Chk1 inhibition. Clin Cancer Res 2011; 17:3706-15; PMID:21482692; http://dx.doi.org/10.1158/1078-0432.CCR-10-3082